Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
UNC Charlotte to Evaluate Potential Adjuvant Activity of ImmuneRegens Viprovex® with Cancer Vaccine
October 25th, 2008
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB:IRBS), announced a collaborative relationship with the University of North Carolina at Charlotte to evaluate ImmuneRegen's Viprovex as a possible cancer vaccine adjuvant. Adjuvants are agents that stimulate and, subsequently, augment the immune system's response to a foreign antigen. The studies will be under the direction of Pinku Mukherjee, Ph.D., an accomplished cellular immunologist focused on developing novel immunotherapies against solid adenocarcinomas, especially pancreatic and breast cancers. This UNC-funded collaboration, part of a material transfer agreement with...
Source: Law & Health Weekly (2008-10-25)
|
